Soltis Investment Advisors LLC Acquires Shares of 2,616 Gilead Sciences, Inc. (NASDAQ:GILD)

Soltis Investment Advisors LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,616 shares of the biopharmaceutical company’s stock, valued at approximately $242,000.

A number of other institutional investors have also made changes to their positions in GILD. FMR LLC lifted its holdings in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP increased its position in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the period. Pacer Advisors Inc. lifted its stake in Gilead Sciences by 723.3% in the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after buying an additional 5,653,075 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares during the period. Finally, International Assets Investment Management LLC grew its position in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after acquiring an additional 1,622,806 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

GILD opened at $96.14 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $119.82 billion, a PE ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18. The business has a fifty day simple moving average of $93.07 and a 200-day simple moving average of $86.99. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Robert W. Baird lifted their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. BMO Capital Markets lifted their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective for the company. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock worth $53,611,715 over the last ninety days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.